Optimizing chemotherapy for patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue SUPPL. 2, 2007, Pages

  Scagliotti, Giorgio ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Advanced disease; Cisplatin; Docetaxel; First line; Non small cell lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; VINDESINE; PACLITAXEL; VINCA ALKALOID;

ADVANCED CANCER; ANEMIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CONFERENCE PAPER; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AREA UNDER THE CURVE; ASTHENIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG WITHDRAWAL; FACE EDEMA; FRAIL ELDERLY; GERIATRIC PATIENT; LEG EDEMA; LUNG TOXICITY; META ANALYSIS; MONOTHERAPY; MORBIDITY; NAUSEA AND VOMITING; NEUROTOXICITY; PAIN; PLEURA EFFUSION; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; TAXOIDS;

EID: 34250876923     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/01.JTO.0000269736.28833.b5     Document Type: Conference Paper

References (23)

1. Hotta K, Matsuo K, Ueoka H, et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
2. Ardizzoni A, Tiseo M, Boni L, et al. CISCA (cisplatin vs. carboplatin) meta-analysis: an individual patient data meta-analysis comparing cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement). J Clin Oncol 2006; 7011. Updated based on presentation.
3. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
4. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001;19:3210-3218.
5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
6. Scagliotti GV, DeMarinis F, Rinaldi M, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
7. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
8. Belani CP, Pereira JR, von Pawel J, et al., TAX 326 study group. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006;53:231-239.
9. Douillard JY, Gervais R, Dabouis G, et al. Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study. Ann Oncol 2005;16:81-89.
10. Kubota K, Watanabe K, Kunitoh H, et al., Japanese Taxotere Lung Cancer Study Group. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004;22:254-261.
11. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23:2937-2945. E-pub 22 February 2005.
12. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic nonsmall-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610.
13. Douillard JY, Fossela F, Georgoulias V, et al. Comparison of docetaxel and vinca alkaloid, alone or in combination with other chemotherapy agents, in the first-line treatment of advanced non-small cell lung cancer (NSCLC): a meta-analysis ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement). J Clin Oncol 2006; 7034.
14. Kudoh S, Takeda K, Nakagawa K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
15. Gridelli C, Shepherd FA. Chemotherapy for elderly patients with non-small cell lung cancer: a review of the evidence. Chest 2005;128:947-957.
16. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer. Elderly Lung Cancer Vinorelbine Italian Study. Oncologist 2001;6 (Suppl. 1):4-7.
17. Frasci G, Lorusso V, Panza N, et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2000;18:2529-2536.
18. Gridelli C, Perrone F, Gallo C, et al. MILES Investigators. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
19. Belani CP, Fossella F. Elderly subgroup analysis of a randomized phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for first-line treatment of advanced nonsmall cell lung carcinoma (TAX 326). Cancer 2005;104:2766-2774.
20. Ohe Y, Niho S, Kakinuma R, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients. Ann Oncol 2004;15:45-50.
21. Clinicaltrials.gov website. Elderly NSCLC/D Vs DP (JCOG0207). Available at: http://www.clinicaltrials.gov/show/NCT00190476. Accessed: 1 October 2006.
22. Gridelli C, Ardizzoni A, Le Chevalier T, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004;15:419-426.
23. Lilenbaum R, Rubin M, Samuel J, et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients (pts) with advanced nonsmall cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 22. Abstract 7057. Updated based on presentation.